MARKET

CABA

CABA

Cabaletta Bio, Inc.
NASDAQ
2.135
-0.085
-3.83%
Opening 09:50 09/24 EDT
OPEN
2.220
PREV CLOSE
2.220
HIGH
2.220
LOW
2.120
VOLUME
780.67K
TURNOVER
--
52 WEEK HIGH
4.230
52 WEEK LOW
2.000
MARKET CAP
361.98M
P/E (TTM)
-1.3625
1D
5D
1M
3M
1Y
5Y
1D
H.C. Wainwright Keeps Their Buy Rating on Cabaletta Bio (CABA)
TipRanks · 3d ago
Weekly Report: what happened at CABA last week (0914-0918)?
Weekly Report · 3d ago
Cabaletta Bio Boosts Cash Through Warrant Exercises
TipRanks · 09/14 12:31
Weekly Report: what happened at CABA last week (0907-0911)?
Weekly Report · 09/14 09:10
Weekly Report: what happened at CABA last week (0831-0904)?
Weekly Report · 09/07 09:09
Analysts Are Bullish on Top Healthcare Stocks: OmniAb (OABI), Cabaletta Bio (CABA)
TipRanks · 09/02 15:10
Analysts’ Top Healthcare Picks: Cabaletta Bio (CABA), Medtronic (MDT)
TipRanks · 09/02 11:10
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 09/02 07:40
More
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Webull offers Cabaletta Bio Inc stock information, including NASDAQ: CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CABA stock methods without spending real money on the virtual paper trading platform.